Status:
COMPLETED
The Change of Bone Markers After Low Dose Alendronate in Postmenopausal Women With Bone Loss
Lead Sponsor:
Eulji University Hospital
Conditions:
Osteoporosis
Eligibility:
FEMALE
50-65 years
Phase:
PHASE4
Brief Summary
High bone turnover with the bone resorption exceeding bone formation is a major mechanism of postmenopausal osteoporosis. Therefore, inhibition of bone resorption is a rational approach for the preven...
Eligibility Criteria
Inclusion
- postmenopausal women (the ages between 50-65 year) with lumbar spine BMD at least 2.0 SD below the peak young adult mean
Exclusion
- severe osteoporosis
- current medication of osteoposis
- metabolic bone disease
- cancer, stroke etc.
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2007
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT00460057
Start Date
March 1 2006
End Date
February 1 2007
Last Update
August 5 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.